FDA Clears SPR Therapeutics’ Non-opioid SPRINT endura and extensa Peripheral Nerve Stimulation Systems for Pain Management
SPRINT® is the First and Only Dual Lead Capable PNS Platform Company also provides first look at 12-month durability outcomes following 60-day SPRINT therapy Cleveland, Ohio- August 16, 2018 – SPR Therapeutics, Inc., a leader in neurostimulation technology for pain, today announced…